Transplant characteristics
| . | n (%) . |
|---|---|
| No. of transplants | 944 |
| No. of patients | 874 |
| Donor type | |
| Matched donors | 623 (65.89) |
| MSD | 232 |
| MFD | 65 |
| MUD | 325 |
| Mismatched donors | 322 (34.11) |
| MMUD | 239 |
| MMSD and MMFD | 16 |
| Haploidentical | 67 |
| Stem cell source | |
| BM | 526 (55.72) |
| PBSCs | 302 (31.99) |
| Cord | 116 (12.29) |
| Preparative conditioning regimens | |
| MAC | 416 (44.07) |
| Bu-based conditioning | 220 |
| Bu/Flu ± Cyc/Mel | 58 |
| Bu/Cyc ± Mel | 162 |
| Treo-based conditioning | 56 |
| Treo/Flu ± TT | 39 |
| Treo/Cy/Mel | 17 |
| TBI conditioning | 121 |
| TBI (12 Gy)/Cyc ± Flu | 84 |
| TBI (12 Gy)/etoposide | 33 |
| TBI (12 Gy)/Flu/TT | 4 |
| Others | 19 |
| Flu/Mel/TT | 6 |
| Carmustine/etoposide/cytarabine/Mel | 3 |
| RIC | 408 (43.22) |
| Treo/Flu | 125 |
| Bu/Flu | 41 |
| Flu/Mel ± anti-CD66 | 187 |
| Flu/cytarabine ± low dose TBI | 3 |
| Other | 10 |
| MIC | 96 (10.28) |
| Flu/Cyc ± low dose TBI or ± anti-CD45 | 67 |
| Cyc alone | 14 |
| Flu/low dose TBI | 8 |
| Cyc/low dose TBI | 7 |
| No conditioning | 66 (6.99) |
| GVHD prophylaxis regimens | 884 (93.65) |
| CSA based | 869 (92.06) |
| CSA | 234 |
| CSA/MMF ± MP | 422 |
| CSA/MTX | 212 |
| CSA/OKT3 | 1 |
| Tacrolimus-based | 5 (0.53) |
| Tac | 2 |
| Tac/MMF | 2 |
| Tac/MTX | 1 |
| Sirolimus based | 4 (0.42) |
| Sirolimus/MMF | 4 |
| Others | 6 (0.64) |
| MMF | 2 |
| MMF/OKT3 | 3 |
| MP | 1 |
| In vivo T-cell depletion | 620 (64.83) |
| Alemtuzumab (0.3-1 mg/kg) | 491 |
| rATG (4-60 mg/kg) | 121 |
| . | n (%) . |
|---|---|
| No. of transplants | 944 |
| No. of patients | 874 |
| Donor type | |
| Matched donors | 623 (65.89) |
| MSD | 232 |
| MFD | 65 |
| MUD | 325 |
| Mismatched donors | 322 (34.11) |
| MMUD | 239 |
| MMSD and MMFD | 16 |
| Haploidentical | 67 |
| Stem cell source | |
| BM | 526 (55.72) |
| PBSCs | 302 (31.99) |
| Cord | 116 (12.29) |
| Preparative conditioning regimens | |
| MAC | 416 (44.07) |
| Bu-based conditioning | 220 |
| Bu/Flu ± Cyc/Mel | 58 |
| Bu/Cyc ± Mel | 162 |
| Treo-based conditioning | 56 |
| Treo/Flu ± TT | 39 |
| Treo/Cy/Mel | 17 |
| TBI conditioning | 121 |
| TBI (12 Gy)/Cyc ± Flu | 84 |
| TBI (12 Gy)/etoposide | 33 |
| TBI (12 Gy)/Flu/TT | 4 |
| Others | 19 |
| Flu/Mel/TT | 6 |
| Carmustine/etoposide/cytarabine/Mel | 3 |
| RIC | 408 (43.22) |
| Treo/Flu | 125 |
| Bu/Flu | 41 |
| Flu/Mel ± anti-CD66 | 187 |
| Flu/cytarabine ± low dose TBI | 3 |
| Other | 10 |
| MIC | 96 (10.28) |
| Flu/Cyc ± low dose TBI or ± anti-CD45 | 67 |
| Cyc alone | 14 |
| Flu/low dose TBI | 8 |
| Cyc/low dose TBI | 7 |
| No conditioning | 66 (6.99) |
| GVHD prophylaxis regimens | 884 (93.65) |
| CSA based | 869 (92.06) |
| CSA | 234 |
| CSA/MMF ± MP | 422 |
| CSA/MTX | 212 |
| CSA/OKT3 | 1 |
| Tacrolimus-based | 5 (0.53) |
| Tac | 2 |
| Tac/MMF | 2 |
| Tac/MTX | 1 |
| Sirolimus based | 4 (0.42) |
| Sirolimus/MMF | 4 |
| Others | 6 (0.64) |
| MMF | 2 |
| MMF/OKT3 | 3 |
| MP | 1 |
| In vivo T-cell depletion | 620 (64.83) |
| Alemtuzumab (0.3-1 mg/kg) | 491 |
| rATG (4-60 mg/kg) | 121 |
Patients receiving Bu-based conditioning had either RIC conditioning with Bu AUC levels of 45 to 65 mg × h/L or MAC conditioning with Bu AUC ≥70 mg × h/L.
AUC, area under the curve; Bu, busulfan; Cyc, cyclophosphamide; CSA, cyclosporine; Flu, fludarabine; MAC, myeloablative conditioning; Mel, melphalan; MFD, matched family donor; MIC, minimal-intensity conditioning; MP, methylprednisolone; MSD, matched sibling donor; MMF, mycophenolate mofetil; MMFD, mismatched family donor; MMSD, mismatched sibling donor; MMUD, mismatched unrelated donor; MTX, methotrexate; MUD, matched unrelated donor; PBSC, peripheral blood stem cell; OKT3, anti-CD3; rATG, rabbit antithymocyte globulin; RIC, reduced-intensity conditioning; Tac, tacrolimus Treo, treosulfan; TT, thiotepa.